Drug Profile
Orludodstat - Bayer
Alternative Names: BAY-2402234Latest Information Update: 28 Jun 2023
Price :
$50
*
At a glance
- Originator Broad Institute
- Developer Bayer
- Class Antineoplastics; Benzamides; Halogenated hydrocarbons; Phenyl ethers; Small molecules; Triazoles
- Mechanism of Action Dihydroorotate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Small cell lung cancer
- No development reported Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Colorectal cancer; Lymphoma; Myelodysplastic syndromes
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Late-stage disease, Second-line therapy or greater) in France (PO, Liquid)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Late-stage disease, Second-line therapy or greater) in USA (PO, Liquid)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Chronic-myelomonocytic-leukaemia(Late-stage disease, Second-line therapy or greater) in France (PO, Liquid)